COVID-19 treatment: Fabiflu by Glenmark, HCQ, Remdesivir and other drugs that are being used to treat coronavirus patients
Favipiravir is an antiviral drug which was developed by a Japanese pharma company, Fujifilm Toyama Chemical, to treat influenza.
Coronavirus Outbreak Updates: Madhya Pradesh govt to promote 1st, 2nd year UG students based on previous scores; 1,128 cases in Mumbai today
Coronavirus Outbreak LIVE Updates: Tamil Nadu reported 2,710 new COVID-19 cases and 37 deaths, taking the total number of cases to 62,087 and death toll to 794. Number of active cases stands at 27,178.
Coronavirus Outbreak Updates: Confirmed cases in Mumbai surge to 66,507 as city reports 1,242 new infections; toll rises to 3,669 with 41 deaths
Coronavirus Outbreak Updates: Mumbai on Sunday recorded 1,242 new coronavirus positive cases and 41 deaths, taking the total positive cases to 66,507 and toll to 3,669.
Glenmark Pharmaceuticals receives approval from USFDA to market generic drug for muscle pain in American market
Glenmark Pharmaceuticals on Wednesday said its subsidiary has received approval from the US health regulator to market Chlorzoxazone tablets, used to treat muscle pain, in the American market
On 1 May, Glenmark Pharmaceuticals said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.
Indian pharmaceutical company Strides Pharma Science Ltd said on Thursday it has got regulatory approval to conduct clinical trials of antiviral drug favipiravir, considered a potential treatment for COVID-19
Glenmark to conduct trials for potential COVID-19 drug, first company in India to receive DCGI approval; shares jump 9%
Glenmark filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, said the BSE filing.
Shares of Glenmark Pharmaceuticals tumbled nearly 10 percent and hit its 52-week low level on the bourses on Monday after the company received a warning letter from the US health regulator for its Baddi facility in Himachal Pradesh
Glenmark Q4 net profit up 6.62% at Rs 162 cr; board approves raising funds up to $200 mn through debt securities
Glenmark Pharma's consolidated revenue for 2018-19 stood at Rs 9,865.46 crore, compared to Rs 9,103.07 crore in the preceding fiscal.
Glenmark will receive an upfront payment and is eligible to receive payments for achieving pre-specified development, regulatory and commercialisation milestones
The decision was taken by the Cabinet Committee on Economic Affairs, chaired by Prime Minister Narendra Modi.
Dr Reddy's had cash and market investments worth $456 million, according to a company presentation in February.